A consolidated list of all the FDA approved medications during the month of August 2025.

  • Modeyso (dordaviprone)
    • For the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy
  • Ajovy (fremanezumab-vfrm)
    • For the preventive treatment of episodic migraine in children and adolescents aged 6-17 who weigh 45 kilograms or more
  • Hernexeos (zongertinib)
    • For the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy
  • KETARx (ketamine)
    • For the treatment of post-surgical pain
  • Brinsupri (brensocatib)
    • To treat non-cystic fibrosis bronchiectasis (NCFBE) in adults and kids ages 12 and older
  • Papzimeos (zopapogene imadenovec-drba)
    • For the treatment of adults with recurrent respiratory papillomatosis (RRP)
  • Wegovy (semaglutide)
    • For the treatment of metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis but without cirrhosis
  • Tonmya (cyclobenzaprine hyrdochloride)
    • For the treatment of fibromyalgia in adults
  • Dawnzera (donidalorsen)
    • For prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older
  • Repatha (evolcumab)
    • To include patients at an increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C)
  • Comirnaty (LP.8.1; COVID-19 vaccine, mRNA)
    • For use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19
  • Spikevax/mNexspike (LP.8.1; COVID-19 vaccine, mRNA)
    • For individuals 12 through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older
  • Nuvaxovid (COVID-19 vaccine, adjuvanted)
    • For the prevention of COVID-19 in adults 65 years and older or individuals 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19
  • Wayrilz (rilzabrutinib)
    • For adults with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment
  • Leqembi Iqlik (lecanemab-irmb)
    • For once weekly subcutaneous injection for maintenance dosing for the treatment of early Alzheimer's Disease

Make sure to sign up for alerts and stay informed on all the latest published guidelines, FDA decisions, and more.

Copyright © 2025 Guideline Central, all rights reserved.